2017. Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab. SKIN The Journal of Cutaneous Medicine. 1, 3.1 (Oct. 2017), s5. DOI:https://doi.org/10.25251/skin.1.supp.4.